Skip to main content

Novel Serotonergic Agonists Positioned to Capture Share of $150B+ Neuropsychiatric Market

Newswire.ca - Tue Feb 10, 7:30AM CST

Improved efficacy, faster onset, and scalable platforms drive investor interest in next-gen CNS assets 

Market News UpdatesNews Commentary

NEW YORK, Feb. 10, 2026 /CNW/ -- Novel serotonergic agonists ("NSAs") are quickly becoming one of the more interesting stories in mental-health and neuroscience investing. In simple terms, these drugs work by activating specific serotonin receptors in the brain to produce faster and more meaningful results than traditional antidepressants. For investors, the appeal is clear: current treatments like SSRIs often take weeks to work and don't help a large portion of patients, while NSAs are being designed to act quicker, last longer, and potentially treat tough conditions like depression, PTSD, anxiety, and addiction more effectively.  Active Companies in the biotech space include:  Helus PharmaTM (NASDAQ: HELP) (Cboe CA: HELP), Johnson & Johnson (NYSE: JNJ), AbbVie Inc. (NYSE: ABBV), Takeda Pharmaceutical Company Limited (NYSE: TAK) and AstraZeneca PLC (NYSE: AZN).

Read more at newswire.ca

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).